Newspaper clipping for Unaudited Financial Results for the quarter ended 30th June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd (BSE Scrip Code: 524516) has submitted to BSE the newspaper clipping of its unaudited financial results for the quarter ended 30 June 2025, as required under SEBI LODR Regulation 47(1)(b). The clipping was published in both Hindi and English newspapers on 14 August 2025. The filing is a routine compliance cover letter signed by Ms. Chaitali Kalpataru Shah, Director & CFO (DIN: 11167778), and does not itself disclose the company's financial numbers. The full quarterly results would have been approved by the Board and filed separately under SEBI LODR Regulation 33.
This is a procedural, regulatory-compliance submission and not a material business announcement, so it is unlikely to move the stock on its own. Investors should look at Bacil Pharma's separately filed Regulation 33 results for the actual Q1FY26 numbers and performance.